A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Bionano Genomics, Inc.
BNGO
$6M
Mkt Cap
$1.11
+0.00%
Bionano Genomics, Inc. (BNGO) has a 5-year average return on invested capital (ROIC) of -57.5%. This is below average and may indicate limited pricing power.
Bionano Genomics, Inc. (BNGO) has a market capitalization of $6M. It is classified as a small-cap stock.
Bionano Genomics, Inc. (BNGO) does not currently pay a regular dividend.
Bionano Genomics, Inc. (BNGO) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
Bionano Genomics, Inc. (BNGO) reported annual revenue of $29 million in its most recent fiscal year, based on SEC EDGAR filings.
Bionano Genomics, Inc. (BNGO) has a net profit margin of -92.6%. The company is currently unprofitable.
Bionano Genomics, Inc. (BNGO) generated $-16 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (“OGM”) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. We offer a platform-agnostic software solution, which integrates next-generation sequencing, microarray and OGM data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis ITP technology. Through our Bionano Laboratories business, we also provide OGM-based diagnostic testing services.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 29M | 29M | - | 36M | - | - |
| Net Income | -26M | -26M | -112M | - | -133M | -72M |
| EPS | $-4.85 | $-4.85 | $-1,498.21 | $-6,946.20 | $-700.74 | $-39.78 |
| Free Cash Flow | -16M | -16M | -69M | -125M | -126M | -73M |
| ROIC | -54.5% | -36.6% | -111.2% | - | -44.9% | -37.3% |
| Gross Margin | 46.3% | 46.3% | - | 26.5% | - | - |
| Debt/Equity | 0.16 | 0.16 | 1.82 | 0.16 | 0.05 | 0.06 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -33M | -33M | -104M | -215M | -132M | -77M |
| Operating Margin | -116.9% | -116.9% | - | -596.0% | - | - |
| ROE | -59.4% | -66.2% | -170.3% | - | -45.2% | -38.9% |
| Shares Outstanding | 5M | 5M | 0M | 0M | 0M | 2M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | 12M | N/A | N/A | N/A | N/A | 36M | N/A | 29M | 29M |
| Gross Margin | N/A | 27.4% | N/A | N/A | N/A | N/A | 26.5% | N/A | 46.3% | 46.3% |
| R&D | 12M | 9.5M | 9.1M | 10M | 22M | 49M | 54M | 25M | 11M | 11M |
| SG&A | 14M | 14M | 20M | 31M | 58M | 89M | 93M | 52M | 35M | 35M |
| EBIT | -23M | -20M | -26M | -39M | -77M | -132M | -215M | -104M | -33M | -33M |
| Op. Margin | N/A | -170.1% | N/A | N/A | N/A | N/A | -596.0% | N/A | -116.9% | -116.9% |
| Net Income | -23M | -18M | -30M | -41M | -72M | -133M | N/A | -112M | -26M | -26M |
| Net Margin | N/A | -154.1% | N/A | N/A | N/A | N/A | N/A | N/A | -92.6% | -92.6% |
| Non-Recurring | 605K | 0 | -12K | 0 | 0 | 0 | 78M | 6.6M | -258K | -258K |
| Returns on Capital | ||||||||||
| ROIC | -180.8% | -82.3% | N/M | -149.4% | -37.3% | -44.9% | N/A | -111.2% | -36.6% | -54.5% |
| ROE | 60.3% | 92.3% | -433.7% | -212.5% | -38.9% | -45.2% | N/A | -170.3% | -66.2% | -59.4% |
| ROA | -230.3% | -105.9% | -108.4% | -90.7% | -33.1% | -38.7% | N/A | -77.0% | -35.1% | -35.9% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -21M | -20M | -30M | -38M | -72M | -125M | -125M | -69M | -16M | -16M |
| Free Cash Flow | -22M | -20M | -30M | -38M | -73M | -126M | -125M | -69M | -16M | -16M |
| Owner Earnings | -23M | -22M | -32M | -41M | -85M | -157M | -154M | -93M | -30M | -30M |
| CapEx | 1.0M | 332K | 61K | 0 | 638K | 792K | 6K | 0 | 0 | 0 |
| Maint. CapEx | 1.5M | 1.3M | 1.1M | 1.5M | 3.4M | 9.6M | 14M | 14M | 9.5M | 9.5M |
| Growth CapEx | 0 | 0 | 0 | N/A | 0 | 0 | 0 | N/A | N/A | 0 |
| D&A | 1.5M | 1.3M | 1.1M | 1.5M | 3.4M | 9.6M | 14M | 14M | 9.5M | 9.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 383K | 1.2M | 1.3M | 1.6M | 9.7M | 22M | 15M | 9.7M | 4.5M | 4.5M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 4.5M | 1.7M | 4.9M | 4.9M |
| Balance Sheet | ||||||||||
| Net Debt | 5.7M | -7.5M | 2.8M | -22M | -229M | -102M | -52M | 44M | -12M | 3.9M |
| Cash & Equiv. | 1.0M | 17M | 17M | 38M | 25M | 5.1M | 18M | 9.2M | 3.0M | 3.0M |
| Long-Term Debt | 0 | 9.0M | 0 | 16M | 0 | 3.6M | 9.0M | 61M | 3.5M | 3.5M |
| Debt/Equity | -0.13 | 0.89 | 5.56 | 0.47 | 0.06 | 0.05 | 0.16 | 1.82 | 0.16 | 0.16 |
| Interest Coverage | -39.3 | -14.8 | -11.3 | -15.3 | -83.2 | -441.9 | -42.0 | -383.7 | -124.9 | -124.9 |
| Equity | -50M | 10M | 3.6M | 35M | 337M | 249M | 96M | 35M | 44M | 44M |
| Total Assets | 10M | 25M | 30M | 60M | 377M | 308M | 214M | 77M | 74M | 74M |
| Total Liabilities | 60M | 15M | 27M | 25M | 40M | 58M | 118M | 41M | 29M | 29M |
| Intangibles | N/A | N/A | 0 | 1.5M | 27M | 41M | 34M | 9.7M | 4.3M | 4.3M |
| Retained Earnings | -54M | -73M | -103M | -144M | -216M | -349M | -581M | -693M | -720M | -720M |
| Working Capital | -9.5M | 19M | 1.9M | 38M | 251M | 121M | 40M | 2.1M | 22M | 22M |
| Current Assets | 7.1M | 23M | 28M | 47M | 272M | 157M | 140M | 39M | 45M | 45M |
| Current Liabilities | 17M | 4.5M | 26M | 8.9M | 22M | 36M | 100M | 37M | 23M | 23M |
| Per Share Data | ||||||||||
| EPS | -11,568.21 | -99.83 | -33.27 | -29.84 | -39.78 | -700.74 | -6,946.20 | -1,498.21 | -4.85 | -4.85 |
| Owner EPS | -11,241.10 | -121.22 | -35.72 | -30.01 | -46.68 | -828.94 | -3,434.79 | -1,239.58 | -5.59 | -5.59 |
| Book Value | -24,867.53 | 54.72 | 4.03 | 25.46 | 185.14 | 1,318.02 | 2,143.74 | 473.14 | 8.16 | 8.16 |
| Cash Flow/Share | -10,306.91 | -107.64 | -32.95 | -27.81 | -39.50 | -659.62 | -2,790.80 | -921.82 | -3.00 | -3.10 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.0M | 0.2M | 0.9M | 1.4M | 1.8M | 0.2M | 0.0M | 0.1M | 5.4M | 5.4M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 18.2 | 83.3 | 2.6 | 2.5 | 1.6 | 3.9 | 0.5 | N/A | 0.1 |
| Price/Sales | N/A | 21.1 | N/A | N/A | N/A | N/A | 35.9 | N/A | N/A | 0.2 |
| FCF Yield | N/A | -11.0% | -9.8% | -41.3% | -8.5% | -31.0% | -33.7% | -430.4% | N/A | -270.6% |
| Market Cap | N/A | 185M | 301M | 93M | 858M | 405M | 372M | 16M | 0 | 6.0M |
| Avg. Price | N/A | 4,025.93 | 1,598.02 | 385.55 | 3,899.72 | 1,252.43 | 431.21 | 44.53 | 0.00 | 1.11 |
| Year-End Price | N/A | 2,940.00 | 648.00 | 528.00 | 1,848.00 | 840.00 | 123.60 | 12.60 | 0.00 | 1.11 |
Bionano Genomics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 36.4%.
Bionano Genomics, Inc. (BNGO) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
Bionano Genomics, Inc. (BNGO) reported earnings per share (EPS) of $-4.85 in its most recent fiscal year.
Bionano Genomics, Inc. (BNGO) has a return on equity (ROE) of -66.2%. A negative ROE may indicate losses or negative equity.
Bionano Genomics, Inc. (BNGO) has a 5-year average gross margin of 36.4%. This indicates decent pricing power.
The Ledger Terminal provides 9 years of financial data for Bionano Genomics, Inc. (BNGO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Bionano Genomics, Inc. (BNGO) has a book value per share of $8.16, based on its most recent annual SEC filing.